about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingAxitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationPhase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.UGT genotyping in belinostat dosingExtreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Axitinib in metastatic renal cell carcinoma: single center experience.Axitinib for the treatment of advanced renal cell carcinoma.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Axitinib plasma pharmacokinetics and ethnic differences.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.Axitinib: a review in advanced renal cell carcinoma.Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.Effect of axitinib on the QT interval in healthy volunteers.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Axitinib sensitization of high Single Dose Radiotherapy.Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.Individualized dosing with axitinib: rationale and practical guidance.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.
P2860
Q23923997-74A28D5D-ECB7-484C-8E1C-6559E472D1C1Q27698001-BBF54498-4B3C-43C9-B3AC-6BAF402A6747Q33420495-BC2E5F5D-34EA-45EE-B4F4-A647CB924C0AQ33429235-CFD13E23-FE45-49C6-A490-32BCBE7A1ED1Q36918281-C8C749F2-09A0-46AC-B920-B57425482D79Q37594395-5E759183-DC8E-47AC-89B8-7639E4B41BB1Q37657679-256F41D3-4A5C-48B4-BD40-5E998BC2DB72Q38170397-AF940057-2AFF-427E-9BAE-25601E5C1CA8Q38190857-DC161E6E-6872-4E18-8F0D-C99AEBE7E3A4Q38348548-ABE2BC85-6719-489B-8817-9F787969EAA3Q38375159-2EA6296C-BD14-4D14-BC04-F5626AF532A6Q38391227-847DBD13-7FD3-4C03-9E98-17990DC2828CQ38612808-43687314-E82B-4ECC-B5B9-8252ADF60EB9Q38815497-651515D2-4423-4D1D-9F7E-07D200461E6AQ38937228-A6A7913C-D43A-4652-996D-8F3408CDC8E7Q39248181-CCBCBCEF-B5D7-4575-9461-5DBCFFB25099Q41496075-31D3AAF8-6148-485D-8589-1EFEB7505C43Q41582221-C6EEC169-6B61-4CF9-BD16-DD0C4EC06D4BQ42364404-F0A1E25E-1171-4C4D-89C0-F6C537C18186Q43083972-130E2452-178E-427A-80B0-03BF45FB2059Q43939236-2AF7C3F4-BEB4-4AF5-BB4F-C9A23ED315E2Q47271327-08890FE8-E427-4DF3-8276-79C2CFC1B622Q47969048-8DA17571-28E0-4BB2-815B-031686940824Q53703721-B39748D1-4F9F-40A6-AA15-2084A6420DD8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical pharmacology of axitinib.
@en
type
label
Clinical pharmacology of axitinib.
@en
prefLabel
Clinical pharmacology of axitinib.
@en
P2093
P2860
P1476
Clinical pharmacology of axitinib.
@en
P2093
Karen J Klamerus
May Garrett
Michael A Tortorici
Yazdi K Pithavala
P2860
P2888
P304
P356
10.1007/S40262-013-0068-3
P577
2013-09-01T00:00:00Z
P6179
1007267484